With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

The BLyS inhibitor could become the first drug for lupus nephritis, which affects about 1 million patients

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis.

Richard Furie, the lead investigator of the BLISS-LN trial, told BioCentury that although lupus nephritis is a complication of systemic lupus

Read the full 496 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers